Literature DB >> 15094177

Treatment of extensive small cell lung cancer.

Angela M Davies1, Primo N Lara, Derick H Lau, David R Gandara.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15094177     DOI： 10.1016/j.hoc.2003.12.012

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


× No keyword cloud information.
  13 in total

1.  Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.

Authors:  Jhanelle Gray; Christopher L Cubitt; Shumin Zhang; Alberto Chiappori
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

2.  Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.

Authors:  Primo N Lara; Kari Chansky; Taro Shibata; Haruhiko Fukuda; Tomohide Tamura; John Crowley; Mary W Redman; Ronald Natale; Nagahiro Saijo; David R Gandara
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

3.  Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients.

Authors:  L-R Zhu; J Li; P Chen; Q Jiang; X-P Tang
Journal:  Clin Transl Oncol       Date:  2015-07-17       Impact factor: 3.405

4.  Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer.

Authors:  Masashi Kasajima; Satoshi Igawa; Mikiko Ishihara; Sakiko Otani; Akira Takakura; Masanori Yokoba; Masaru Kubota; Jiichiro Sasaki; Masato Katagiri; Noriyuki Masuda
Journal:  Oncol Lett       Date:  2017-02-01       Impact factor: 2.967

Review 5.  Signal pathways and precision therapy of small-cell lung cancer.

Authors:  Min Yuan; Yu Zhao; Hendrik-Tobias Arkenau; Tongnei Lao; Li Chu; Qing Xu
Journal:  Signal Transduct Target Ther       Date:  2022-06-15

6.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Authors:  Primo N Lara; Ronald Natale; John Crowley; Heinz Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

7.  Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.

Authors:  Alberto A Chiappori; Zhong Zheng; Tingan Chen; Bhupendra Rawal; Michael J Schell; Brian P Mullaney; Gerold Bepler
Journal:  J Thorac Oncol       Date:  2010-04       Impact factor: 15.609

8.  Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.

Authors:  Sanaz Taromi; Florentine Lewens; Ruza Arsenic; Dagmar Sedding; Jörg Sänger; Almut Kunze; Markus Möbs; Joana Benecke; Helma Freitag; Friederike Christen; Daniel Kaemmerer; Amelie Lupp; Mareike Heilmann; Hedwig Lammert; Claus-Peter Schneider; Karen Richter; Michael Hummel; Britta Siegmund; Meike Burger; Franziska Briest; Patricia Grabowski
Journal:  Oncotarget       Date:  2017-09-23

9.  Increased Expression of Eps15 Homology Domain 1 is Associated with Poor Prognosis in Resected Small Cell Lung Cancer.

Authors:  Qingwei Meng; Weiling Sun; Man Li; Yanbin Zhao; Xuesong Chen; Lichun Sun; Li Cai
Journal:  J Cancer       Date:  2015-08-20       Impact factor: 4.207

10.  Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.

Authors:  Yuankai Shi; Yi Hu; Xingsheng Hu; Xue Li; Lin Lin; Xiaohong Han
Journal:  Thorac Cancer       Date:  2015-08-20       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.